Table 4. Contrast results of MRI contrast-enhanced scan between PCC and HG with marginal enhancement.
| Observed content | PCC groups (n=21) | HG groups (n=26) | Statistics | P value |
|---|---|---|---|---|
| Marginal enhancement features of artery stage | – | 0.019 | ||
| Nodular | 6 | 17 | ||
| Annular | 15 | 9 | ||
| Central enhancement features of artery stage | 30.019 | 0.000 | ||
| Nebulous | 12 | 2 | ||
| Separated/astral | 6 | 0 | ||
| Nodular | 0 | 5 | ||
| No enhancement | 3 | 19 | ||
| Marginal enhancement variation tendency | – | 0.000 | ||
| Delayed enhancement | 1 | 8 | ||
| Delay reduction | 12 | 0 | ||
| Delay invariable | 8 | 18 | ||
| Central enhancement variation tendency | 0.948 | 0.793 | ||
| Delayed enhancement | 16 | 17 | ||
| Delay reduction | 2 | 5 | ||
| Delay invariable | 3 | 4 |
MRI, magnetic resonance imaging; PCC, peripheral nodular cholangiocarcinoma; HG, hepatic hemangioma.